Janssen’s Tremfya meets primary endpoint in Discover studies
Janssen is developing Tremfya to treat inflammatory diseases such as plaque psoriasis and psoriatic arthritis. Credit: Bic.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more